Pfizer Inc PFE.N struck a $43 billion deal for Seagen Inc SGEN.O to add innovative targeted therapies to its portfolio of cancer treatments as it braces for a steep fall in COVID-19 product sales and stiff competition for some top sellers. Monday’s deal, Pfizer’s biggest in a string of acquisitions following a once-in-a-lifetime cash windfall … continue reading -> “Pfizer Looks Past COVID With $43 Billion Deal for Cancer Drug Innovator Seagen”
